81 related articles for article (PubMed ID: 16028404)
41. Implications of EGFR inhibition in ovarian cancer cell proliferation.
Bull Phelps SL; Schorge JO; Peyton MJ; Shigematsu H; Xiang LL; Miller DS; Lea JS
Gynecol Oncol; 2008 Jun; 109(3):411-7. PubMed ID: 18423824
[TBL] [Abstract][Full Text] [Related]
42. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
43. Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.
Wang J; Liu Q; Zhou X; He Y; Guo Q; Shi Q; Eriksson S; Zhou J; He E; Skog S
Tumour Biol; 2017 Jun; 39(6):1010428317706479. PubMed ID: 28651488
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of immunohistochemical expression profile of epidermal growth factor receptor in urothelial bladder cancer.
Arfaoui AT; Mejri S; Belhaj R; Karkni W; Chebil M; Rammeh S
J Immunoassay Immunochem; 2016; 37(4):359-67. PubMed ID: 26919632
[TBL] [Abstract][Full Text] [Related]
45. Expression of alpha-smooth muscle actin in benign or malignant ovarian tumors.
Kobayashi H; Tsuruchi N; Sugihara K; Kaku T; Saito T; Kamura T; Tsukamoto N; Nakano H; Taniguchi S
Gynecol Oncol; 1993 Mar; 48(3):308-13. PubMed ID: 8462899
[TBL] [Abstract][Full Text] [Related]
46. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
47. [Significance of expression of epidermal growth factor receptor, transforming growth factor beta, c-erbB-2 oncogene in myoepithelioma of salivary gland].
Wang L; Gao Y; Yang L
Zhonghua Kou Qiang Yi Xue Za Zhi; 1999 Mar; 34(2):100-2. PubMed ID: 11834172
[TBL] [Abstract][Full Text] [Related]
48. Expression of cell regulatory proteins in ovarian borderline tumors.
van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
[TBL] [Abstract][Full Text] [Related]
49. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.
Berchuck A; Rodriguez GC; Kamel A; Dodge RK; Soper JT; Clarke-Pearson DL; Bast RC
Am J Obstet Gynecol; 1991 Feb; 164(2):669-74. PubMed ID: 1992720
[TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths.
Alshenawy HA
Ann Diagn Pathol; 2010 Dec; 14(6):387-95. PubMed ID: 21074685
[TBL] [Abstract][Full Text] [Related]
51. [Relation between the expression of hypoxia inducible factor-1alpha and angiogenesis in ovarian cancer using tissue microarray].
Luo J; Peng ZL; Yang KX; Wang H; Yang H; Dong DD; Yao XY
Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):38-41. PubMed ID: 15774091
[TBL] [Abstract][Full Text] [Related]
52. The synergistic effects of CXCR4 and EGFR on promoting EGF-mediated metastasis in ovarian cancer cells.
Guo Z; Cai S; Fang R; Chen H; Du J; Tan Y; Ma W; Hu H; Cai S; Liu Y
Colloids Surf B Biointerfaces; 2007 Oct; 60(1):1-6. PubMed ID: 17601710
[TBL] [Abstract][Full Text] [Related]
53. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.
Kersemaekers AM; Fleuren GJ; Kenter GG; Van den Broek LJ; Uljee SM; Hermans J; Van de Vijver MJ
Clin Cancer Res; 1999 Mar; 5(3):577-86. PubMed ID: 10100709
[TBL] [Abstract][Full Text] [Related]
54. CD31 expression in benign, borderline, and malignant epithelial ovarian tumors: an immunohistochemical and serological analysis.
Darai E; Bringuier AF; Walker-Combrouze F; Fauconnier A; Couvelard A; Feldmann G; Madelenat P; Scoazec JY
Gynecol Oncol; 1998 Oct; 71(1):122-7. PubMed ID: 9784332
[TBL] [Abstract][Full Text] [Related]
55. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer.
Psyrri A; Kassar M; Yu Z; Bamias A; Weinberger PM; Markakis S; Kowalski D; Camp RL; Rimm DL; Dimopoulos MA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8637-43. PubMed ID: 16361548
[TBL] [Abstract][Full Text] [Related]
56. Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients.
Klasa-Mazurkiewicz D; Jarząb M; Milczek T; Lipińska B; Emerich J
Pol J Pathol; 2011; 62(1):31-40. PubMed ID: 21574104
[TBL] [Abstract][Full Text] [Related]
57. [Expression of epidermal growth factor receptor in gestational trophoblastic tumours].
Xiang Y; Li Z; Cui Q; Yang X; Song H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Dec; 22(6):555-7. PubMed ID: 12903403
[TBL] [Abstract][Full Text] [Related]
58. Expression of the 67 kD laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5.
van den Brûle FA; Castronovo V; Ménard S; Giavazzi R; Marzola M; Belotti D; Taraboletti G
Eur J Cancer; 1996 Aug; 32A(9):1598-602. PubMed ID: 8911124
[TBL] [Abstract][Full Text] [Related]
59. Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay.
Henzen-Logmans SC; Berns EM; Klijn JG; van der Burg ME; Foekens JA
Br J Cancer; 1992 Dec; 66(6):1015-21. PubMed ID: 1457340
[TBL] [Abstract][Full Text] [Related]
60. Epidermal growth factor receptor in normal ovaries and benign ovarian tumours.
Owens OJ; Leake RE
Eur J Obstet Gynecol Reprod Biol; 1992 Dec; 47(3):229-33. PubMed ID: 1294410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
